公开(公告)号：US10464932B2

公开(公告)日：2019-11-05

申请号：US16076387

申请日：2017-02-22

Applicant: UCB Biopharma SPRL

Inventor： Teresa De Haro Garcia ,  Martin Alexander Lowe ,  Malcolm Maccoss ,  Richard David Taylor ,  Zhaoning Zhu

IPC: C07D417/10 ,  C07D417/14 ,  A61P33/06

Abstract: A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

公开(公告)号：US20190040053A1

公开(公告)日：2019-02-07

申请号：US16076387

申请日：2017-02-22

Applicant: UCB Biopharma SPRL

Inventor： Teresa De Haro Garcia ,  Martin Alexander Lowe ,  Malcolm Maccoss ,  Richard David Taylor ,  Zhaoning Zhu

IPC: C07D417/10 ,  C07D417/14 ,  A61P33/06

CPC classification number: C07D417/10 ,  A61P33/06 ,  C07D417/14

Abstract: A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

公开(公告)号：US20200046723A1

公开(公告)日：2020-02-13

申请号：US16497217

申请日：2018-04-24

Applicant: UCB Biopharma SPRL ,  SANOFI

Inventor： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC: A61K31/55 ,  C07D487/18

Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20200283416A1

公开(公告)日：2020-09-10

申请号：US15774332

申请日：2016-11-24

Applicant: UCB Biopharma SPRL

Inventor： Rebecca Louise Charlton ,  Teresa De Haro Garcia ,  Martin Alexander Lowe ,  Malcolm Maccoss ,  Trevor Morgan ,  Richard David Taylor ,  Zhaoning Zhu

IPC: C07D403/10 ,  C07D471/04 ,  C07D417/10

Abstract: A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

公开(公告)号：US11136310B2

公开(公告)日：2021-10-05

申请号：US15774332

申请日：2016-11-24

Applicant: UCB Biopharma SPRL

Inventor： Rebecca Louise Charlton ,  Teresa De Haro Garcia ,  Martin Alexander Lowe ,  Malcolm Maccoss ,  Trevor Morgan ,  Richard David Taylor ,  Zhaoning Zhu

IPC: C07D403/10 ,  C07D417/10 ,  C07D471/04

Abstract: A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.